VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2020 | Bladder cancer: combining IDO inhibitors with immunotherapy

Sima Porten, MD, MPH, FACS, University of California, San Francisco, CA, discusses the option of using indoleamine 2,3-dioxygenase (IDO) inhibitors in combination with immunotherapy as a treatment in non-muscle invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter